Baird Capital Leads $21M Series B in Jumpcode Genomics

Baird Capital and Syndicate Invest in GreenLight Biosciences

January 8, 2019

Biotechnology

Baird Capital invested in GreenLight Biosciences as part of a $50 million funding round led by S2G Ventures to scale the company's RNA production platform for agricultural and life-science applications. The capital will support expansion of GreenLight's scalable, low-cost RNA manufacturing capabilities and enable entry/expansion into pharmaceutical and crop-protection markets.

Baird Capital Invests $53M in EvoluteIQ

September 17, 2025

AI & Machine Learning

Baird Capital has made a $53 million growth investment in EvoluteIQ, an AI-native platform that automates end-to-end business processes. The funding will be used to accelerate EvoluteIQ's global expansion and scale its enterprise agentic AI capabilities across industries including banking, insurance, healthcare, telecom and manufacturing.

Ampersand Capital Partners Leads $18.5M Growth Investment in Genezen

November 2, 2023

Biotechnology

Genezen closed an $18.5 million follow-on growth equity financing led by Ampersand Capital Partners to accelerate expansion of its viral vector development and GMP manufacturing capabilities. The capital will support build-out and technology investments at Genezen's facilities (including the Fishers, Indiana GMP viral vector site) to scale retroviral, lentiviral and AAV vector production and support additional customer programs.

Baird Capital Leads $22M Series B Investment in Crayon

May 4, 2021

Cloud & SaaS

Baird Capital led a $22 million Series B financing in Crayon, the competitive intelligence SaaS platform used by mid-sized and large enterprises. The round included participation from Baseline Ventures, Bedrock Capital, C&B Capital and Gaingels; Crayon will use the proceeds to accelerate product development and expand its team.

Baird Capital Leads $17M Series B in BlackCloak

September 17, 2024

Cybersecurity

Baird Capital's venture team led a $17 million Series B investment in BlackCloak, a digital executive protection platform that provides cybersecurity and privacy services for high-profile individuals and executives. The capital will be used to accelerate technology and platform investments, expanding BlackCloak's product and intelligence capabilities.

Baird Capital Invests in Azzur Group

April 26, 2021

Healthcare Services

Baird Capital’s private equity team has made a growth investment in Azzur Group to accelerate expansion of the company’s early‑phase life science services, including Azzur Cleanrooms on Demand. Financial terms were not disclosed; Baird Capital advisors Brett Tucker and Dave Schroeder joined Azzur’s board and Gary Knight joined as an independent director. Brown Gibbons Lang & Company served as Azzur’s financial advisor and Edgemont Partners advised Baird Capital.